Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1. Sotagliflozin with insulin for treating type 1 diabetes

an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sotagliflozin with insulin for treating type 1 diabetes (TA622) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about sotagliflozin 6 3 Committee discussion 7 Clinical management 7 Experience of people (...) -and- conditions#notice-of-rights). Page 3 of 211 1 Recommendations Recommendations 1.1 Sotagliflozin with insulin is recommended as an option for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, only if: sotagliflozin is given as one 200 mg tablet daily they are on insulin doses of 0.5 units/kg of body weight/day or more and they have completed a structured education programme

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

2. Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY

Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY | American Association of Clinical Endocrinologists search Search Resources BACK Offering Guidance Through the Latest Science on Bone-Related Disorders Treat your diabetes patients with expert precision. Offering Guidance Through the Latest Science on Lipid Conditions Education Menu FEATURED EMBR AACE 2020 EMBR AACE , the AACE 29 th Annual (...) to enhancing our members’ knowledge, education, and practice management skills so they can focus on providing the highest quality of patient care. We also advocate for the profession to create understanding of the value of our community to patients, organizations and the public. search Breadcrumb Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY Footer Navigation Partner With Us Join us to develop an open dialogue between industry and foster AACE in the furtherance of patient

2020 American Association of Clinical Endocrinologists

3. Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research (...) proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Type 2 Diabetes Mellitus Patient population. Adults Objectives. To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic

2020 University of Michigan Health System

4. Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1} {1} {1} | | > > > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight In the January issue of Prescrire International - Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications FREE DOWNLOAD In the "Reviews" section this month: what is dapagliflozin's harm-benefit balance in type 2 diabetes, in light of the results of a recent randomised, double-blind trial studying the drug's effect on cardiovascular outcomes? Full text available for free download. Summary A randomised, double-blind trial of dapagliflozin

2020 Prescrire

5. Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Full Text available with Trip Pro

Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Nov 6 [Online ahead of print] Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

2020 EvidenceUpdates

6. Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study

collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions , 43 (2), 337-342 Feb 2020 Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin (...) , Sanofi Spain, Barcelona, Spain. PMID: 31831473 DOI: Item in Clipboard Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA 1c in Andalusia (Spain): PLATEDIAN Study Maria S Ruiz de Adana et al. Diabetes Care . Feb 2020 Show details Diabetes Care Actions , 43 (2), 337-342 Authors , , , , , , , , , , , , Affiliations 1 Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Málaga, Spain

2020 EvidenceUpdates

7. Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial

Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions , 7 (12), 925-937 Dec 2019 Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2

2020 EvidenceUpdates

8. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes

A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes A 12-week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as Monotherapy for Adults With Type 2 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Nov 20 [Online ahead of print] A 12-week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as Monotherapy for Adults With Type 2

2020 EvidenceUpdates

9. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria

Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Diabet Med Actions , 37 (1), 44-52 Jan 2020 Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria

2020 EvidenceUpdates

10. Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value

Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value ©Institute for Clinical and Economic Review, 2019 Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value Final Evidence Report December 9, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 Page i Final Evidence Report – Oral Semaglutide for Type 2 Diabetes Return to Table of Contents ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group David M. Rind, MD, MSc Chief Medical (...) of Washington Ryan N. Hansen, PharmD, PhD Assistant Professor The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy University of Washington None of the above authors disclosed any conflicts of interest. DATE OF PUBLICATION: December 9, 2019 How to cite this document: Rind D, Guzauskas G, Fazioli K, Hansen R, Kumar V, Chapman R, Borrelli E, Bradt P, Pearson S. Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value. Institute for Clinical and Economic Review

2020 California Technology Assessment Forum

11. Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. Full Text available with Trip Pro

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. To assess the cost-effectiveness of pharmaceutical care (PC) intervention versus usual care (UC) in the management of type 2 diabetes.This study was a randomized, controlled study with a 12-month patient follow-up in two Nigerian tertiary hospitals. One hundred and ten patients were randomly assigned to each of the "intervention" (PC) and the "control" (UC) groups (...) , respectively, with an associated incremental cost-utility ratio of NGN 88,525 ($571) per QALY gained. In the cost-effectiveness acceptability curve, the probability that PC was more cost-effective than UC was 95% at the NGN 250,000 ($1613) per QALY gained threshold and 52% at the NGN 88,600 ($572) per QALY gained threshold.The PC intervention was very cost-effective among patients with type 2 diabetes at the NGN 88,525 ($571.13) per QALY gained threshold, although considerable uncertainty surrounds

2019 Value in health regional issues Controlled trial quality: uncertain

12. Effect of yoga and aerobics exercise on sleep quality in women with Type 2 diabetes: a randomized controlled trial. Full Text available with Trip Pro

Effect of yoga and aerobics exercise on sleep quality in women with Type 2 diabetes: a randomized controlled trial. The aim of this study was investigating the effect of 12 weeks of yoga and aerobic exercise (running on a treadmill) on the sleep quality in women with Type 2 diabetes.39 diabetic women were selected from Semnan city with the mean age of 46.85±3.35 years, weight of 69.79±17.18 kg, height of 155.03±5.00, BMI of 29.64±5.00 kg/m2 who had a background of diabetes for 6.46±2.69 years (...) of aerobic exercise in women suffering from diabetes Type 2. Thus, yoga exercise can be suggested to these patients.

2019 Sleep science (Sao Paulo, Brazil) Controlled trial quality: uncertain

13. The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes. Full Text available with Trip Pro

The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes. To evaluate the impact of pharmaceutical care (PC) intervention on health-related quality of life (HRQOL) of patients with type 2 diabetes.This study was a randomized, controlled study with a 12-month patient follow-up. The study protocol was approved by the Research Ethical Committees of the institutions in which this study was conducted. A total of 110 patients (...) duration (>4 years), emergency room visits, comorbidity of hypertension, and stroke in both PC and UC groups.Addition of PC to UC improved the quality of life in patients with type 2 diabetes.Copyright © 2013, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

2019 Value in health regional issues Controlled trial quality: uncertain

14. Metformin hydrochloride / saxagliptin / dapagliflozin (Qtrilmet) - type 2 diabetes

Metformin hydrochloride / saxagliptin / dapagliflozin (Qtrilmet) - type 2 diabetes Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/521799/2019 EMEA/H/C/004910 Qtrilmet (...) (metformin / saxagliptin / dapagliflozin) An overview of Qtrilmet and why it is authorised in the EU What is Qtrilmet and what is it used for? Qtrilmet is a diabetes medicine that contains the active substances metformin, saxagliptin and dapagliflozin. It is used to treat type 2 diabetes in: • adults whose blood sugar is not controlled well enough with metformin combined with either saxagliptin or dapagliflozin (including those also taking a sulphonylurea, another type of diabetes medicine); • adults who

2019 European Medicines Agency - EPARs

15. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial

Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial Gastric Bypass Versus Sleeve Gastrectomy in Patients With Type 2 Diabetes (Oseberg): A Single-Centre, Triple-Blind, Randomised Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions , 7 (12), 912-924 Dec 2019 Gastric Bypass Versus Sleeve Gastrectomy in Patients With Type 2 Diabetes (Oseberg): A Single-Centre, Triple-Blind, Randomised Controlled Trial , , , , , , , , , , , , , , Affiliations Expand

2019 EvidenceUpdates

16. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Full Text available with Trip Pro

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium-glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin.Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end (...) at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product -4.7 vs. -3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide.Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide

2019 EvidenceUpdates

17. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial Full Text available with Trip Pro

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin.Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double (...) . 7.1% with placebo; mostly mild to moderate).Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.© 2019 by the American Diabetes Association.

2019 EvidenceUpdates

18. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis Full Text available with Trip Pro

Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis To assess the efficacy and safety of oral semaglutide, a novel glucagon-like peptide-1 receptor agonist, for patients with type 2 diabetes.We searched Medline, Embase, the Cochrane Library and grey literature sources up to July 1, 2019 for randomized controlled trials (RCTs) comparing oral semaglutide with placebo or other antidiabetic agents. The primary outcome was change from baseline in HbA1c. Secondary outcomes (...) included change from baseline in body weight and blood pressure, cardiovascular endpoints, severe hypoglycaemia, gastrointestinal adverse events and diabetic retinopathy. We synthesized results using weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes, along with 95% confidence intervals (CIs).We included 11 RCTs with 9890 patients in the systematic review. Compared with placebo, oral semaglutide reduced HbA1c and body weight (WMD -0.89%, 95% CI -1.07

2019 EvidenceUpdates

19. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study Full Text available with Trip Pro

Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study Comparative Cardiovascular and Hypoglycaemic Safety of Glimepiride in Type 2 Diabetes: A Population-Based Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily (...) : Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions , 22 (2), 254-262 Feb 2020 Comparative Cardiovascular and Hypoglycaemic Safety of Glimepiride in Type 2 Diabetes: A Population-Based Cohort Study , , , Affiliations Expand Affiliations 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital

2019 EvidenceUpdates

20. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial (Abstract)

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabetes mellitus and coronary artery (...) measures included 6-month changes in LV end-diastolic and -systolic volumes indexed to body surface area, ejection fraction, 24-hour ambulatory blood pressure, hematocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide).Among the 97 participants (90 men [93%], mean [standard deviation] age 62.8 [9.0] years, type 2 diabetes mellitus duration 11.0 [8.2] years, estimated glomerular filtration rate 88.4 [16.9] mL/min/1.73m2, LV mass indexed to body surface area 60.7 [11.9] g/m2), 90 had evaluable

2019 EvidenceUpdates